Vivo Opportunity Fund, L.p. - Net Worth and Insider Trading

Vivo Opportunity Fund, L.p. Net Worth

The estimated net worth of Vivo Opportunity Fund, L.p. is at least $183 Million dollars as of 2024-11-13. Vivo Opportunity Fund, L.p. is the 10% Owner of Sierra Oncology Inc and owns about 3,329,512 shares of Sierra Oncology Inc (SRRA) stock worth over $183 Million. Details can be seen in Vivo Opportunity Fund, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Vivo Opportunity Fund, L.p. has not made any transactions after 2022-01-31 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Vivo Opportunity Fund, L.p.

To

Vivo Opportunity Fund, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Vivo Opportunity Fund, L.p. owns 6 companies in total, including ALX Oncology Holdings Inc (ALXO) , Crinetics Pharmaceuticals Inc (CRNX) , and Sierra Oncology Inc (SRRA) among others .

Click here to see the complete history of Vivo Opportunity Fund, L.p.’s form 4 insider trades.

Insider Ownership Summary of Vivo Opportunity Fund, L.p.

Ticker Comapny Transaction Date Type of Owner
ALXO ALX Oncology Holdings Inc 2020-07-21 10 percent owner
CRNX Crinetics Pharmaceuticals Inc 2020-01-29 10 percent owner
SRRA Sierra Oncology Inc 2022-01-31 10 percent owner
LIMIT LIMIT 2019-01-07 10 percent owner
LIMIT LIMIT 2021-02-09 10 percent owner
LIMIT LIMIT 2021-02-09 10 percent owner

Vivo Opportunity Fund, L.p. Latest Holdings Summary

Vivo Opportunity Fund, L.p. currently owns a total of 1 stock. Vivo Opportunity Fund, L.p. owns 3,329,512 shares of Sierra Oncology Inc (SRRA) as of January 31, 2022, with a value of $183 Million.

Latest Holdings of Vivo Opportunity Fund, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SRRA Sierra Oncology Inc 2022-01-31 3,329,512 54.99 183,089,865

Holding Weightings of Vivo Opportunity Fund, L.p.


Vivo Opportunity Fund, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Vivo Opportunity Fund, L.p. has made a total of 1 transactions in Sierra Oncology Inc (SRRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Sierra Oncology Inc is the acquisition of 800,000 shares on January 31, 2022, which cost Vivo Opportunity Fund, L.p. around $22 Million.

Insider Trading History of Vivo Opportunity Fund, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Vivo Opportunity Fund, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Vivo Opportunity Fund, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Vivo Opportunity Fund, L.p. is 101.96%. GuruFocus also compares Vivo Opportunity Fund, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Vivo Opportunity Fund, L.p. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Vivo Opportunity Fund, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Vivo Opportunity Fund, L.p.

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 16.45 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 19.82 LIMIT LIMIT LIMIT LIMIT LIMIT

Vivo Opportunity Fund, L.p. Ownership Network

Ownership Network List of Vivo Opportunity Fund, L.p.

No Data

Ownership Network Relation of Vivo Opportunity Fund, L.p.

Insider Network Chart

Vivo Opportunity Fund, L.p. Owned Company Details

What does ALX Oncology Holdings Inc do?

Who are the key executives at ALX Oncology Holdings Inc?

Vivo Opportunity Fund, L.p. is the 10 percent owner of ALX Oncology Holdings Inc. Other key executives at ALX Oncology Holdings Inc include VP & Finance and CAO Shelly Pinto , Chief Medical Officer Sophia Randolph , and director & President and CEO Jaume Pons .

ALX Oncology Holdings Inc (ALXO) Insider Trades Summary

Over the past 18 months, Vivo Opportunity Fund, L.p. made no insider transaction in ALX Oncology Holdings Inc (ALXO). Other recent insider transactions involving ALX Oncology Holdings Inc (ALXO) include a net sale of 145,903 shares made by Jaume Pons , a net sale of 14,288 shares made by Shelly Pinto , and a net sale of 18,243 shares made by Sophia Randolph .

In summary, during the past 3 months, insiders sold 3,866 shares of ALX Oncology Holdings Inc (ALXO) in total and bought 0 shares, with a net sale of 3,866 shares. During the past 18 months, 179,321 shares of ALX Oncology Holdings Inc (ALXO) were sold and 28,400 shares were bought by its insiders, resulting in a net sale of 150,921 shares.

ALX Oncology Holdings Inc (ALXO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

ALX Oncology Holdings Inc Insider Transactions

No Available Data

Vivo Opportunity Fund, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Vivo Opportunity Fund, L.p.. You might contact Vivo Opportunity Fund, L.p. via mailing address: 192 Lytton Avenue, Palo Alto Ca 94301.